3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Conditions
Leukemia, Myeloid, Acute
33
Myelodysplastic Syndromes
9
Recurrence
7
Lymphoma, Large B-Cell, Diffuse
5
Hodgkin Disease
5
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Wilms Tumor
1
TP53
1
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
1
Primary Malignant Neoplasm of Ovary
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Blood Stem Cell Transplantation
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Malignant Solid Tumor
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid
1
Hematopoietic System--Cancer
1
Graft vs Host Disease
1
Extranodal Extension
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Paclitaxel
1
Decitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Primary Malignant Neoplasm of Ovary
×
Decitabine
×
Clear all
NCT02159820
2014-06-10
DAC and CT
Chinese PLA General Hospital
Phase 2/3
Unknown
500 enrolled